Literature DB >> 18334914

Common ATP-binding cassette B1 variants are associated with increased digoxin serum concentration.

Albert-Jan L H J Aarnoudse1, Jeanne P Dieleman, Loes E Visser, Pascal P Arp, Ilse P van der Heiden, Ron H N van Schaik, Mariam Molokhia, Albert Hofman, André G Uitterlinden, Bruno H Ch Stricker.   

Abstract

BACKGROUND AND
OBJECTIVE: Digoxin is a known substrate of ATP-binding cassette B1 (ABCB1/MDR1). The results of studies on the association between ABCB1 polymorphisms and digoxin kinetics, however, remain contradictory. Almost all studies were small and involved only single dose kinetics. The goal of this study was to establish ABCB1 genotype effect on digoxin blood concentrations in a large cohort of chronic digoxin users in a general Dutch European population.
METHODS: Digoxin users were identified in the Rotterdam Study, a prospective population-based cohort study of individuals aged 55 years and above. Digoxin blood levels were gathered from regional hospitals and laboratories. ABCB1 single nucleotide polymorphisms (SNPs) 1236C-->T, 2677G-->T/A, and 3435C-->T were assessed on peripheral blood DNA using Taqman assays. We studied the association between the ABCB1 genotypes and haplotypes, and digoxin blood levels using linear regression models adjusting for potential confounders.
RESULTS: Digoxin serum levels and DNA were available for 195 participants (56.4% women, mean age 79.4 years). All three ABCB1 variants were significantly associated with serum digoxin concentration (0.18-0.21 microg/l per additional T allele). The association was even stronger for the 1236-2677-3435 TTT haplotype allele [0.26 mug/l (95% CI 0.14-0.38)], but absent for other haplotypes (CGC allele considered referent), suggesting an interaction of SNPs in a causal haplotype instead of individual SNP effects.
CONCLUSION: We found that the common ABCB1 1236C-->T, 2677G-->T, and 3435C-->T variants and the associated TTT haplotype were associated with higher digoxin serum concentrations in a cohort of elderly European digoxin users in the general population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18334914     DOI: 10.1097/FPC.0b013e3282f70458

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN: 1744-6872            Impact factor:   2.089


  26 in total

1.  Sex differences in cardiovascular drug-induced adverse reactions causing hospital admissions.

Authors:  Eline M Rodenburg; Bruno H Stricker; Loes E Visser
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

Review 2.  Is antiarrhythmic treatment in the elderly different? a review of the specific changes.

Authors:  Vera H M Deneer; Norbert M van Hemel
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

3.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

Review 4.  Predicting and Understanding the Human Microbiome's Impact on Pharmacology.

Authors:  Reese Hitchings; Libusha Kelly
Journal:  Trends Pharmacol Sci       Date:  2019-06-03       Impact factor: 14.819

5.  Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia.

Authors:  Hui He; Jiye Yin; Xi Li; Yu Zhang; Xiaojing Xu; Ming Zhai; Juan Chen; Chenyue Qian; Honghao Zhou; Zhaoqian Liu
Journal:  Eur J Clin Pharmacol       Date:  2015-01-09       Impact factor: 2.953

Review 6.  Practical Pharmacogenomic Approaches to Heart Failure Therapeutics.

Authors:  Chayakrit Krittanawong; Amalia Namath; David E Lanfear; W H Wilson Tang
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-10

7.  Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein).

Authors:  Laura M Hodges; Svetlana M Markova; Leslie W Chinn; Jason M Gow; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2011-03       Impact factor: 2.089

Review 8.  Pharmacogenomics in heart failure: where are we now and how can we reach clinical application?

Authors:  Akinyemi Oni-Orisan; David E Lanfear
Journal:  Cardiol Rev       Date:  2014 Sep-Oct       Impact factor: 2.644

Review 9.  Advances in the Genetics and Genomics of Heart Failure.

Authors:  Nosheen Reza; Anjali Tiku Owens
Journal:  Curr Cardiol Rep       Date:  2020-09-10       Impact factor: 2.931

10.  The Rotterdam Study: 2010 objectives and design update.

Authors:  Albert Hofman; Monique M B Breteler; Cornelia M van Duijn; Harry L A Janssen; Gabriel P Krestin; Ernst J Kuipers; Bruno H Ch Stricker; Henning Tiemeier; André G Uitterlinden; Johannes R Vingerling; Jacqueline C M Witteman
Journal:  Eur J Epidemiol       Date:  2009       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.